Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

January 2, 2024

Study Completion Date

January 2, 2024

Conditions
Fibrillary Glomerulonephritis
Interventions
DRUG

Anti-CD20 antibodies

comparing anti-CD20 (lymphoma protcol, RTX 375 mg/m2 every 4 weeks ) alone Vs. Intensive B-cell depletion therapy (IBCDT) which is based on the combination of RTX (given at the dose of 375 mg/m2 every 4 weeks followed by 2 additional doses after 1 and 2 months), cyclophosphamide (two pulses of 10 mg/kg, corrected according to renal function, on days 4 and 17) and methylprednisolone (three bolus doses of 15 mg/kg) followed by oral prednisone (starting dose 50 mg tapered until complete discontinuation in 4 months).

Trial Locations (1)

10154

San Giovanni Bosco Hub Hospital, Torino

All Listed Sponsors
lead

University of Turin, Italy

OTHER